A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Vilazodone (Primary) ; Fluoxetine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 21 Feb 2018 Planned number of patients changed from 400 to 470.
- 21 Feb 2018 Planned End Date changed from 1 Jun 2017 to 8 Sep 2018.
- 21 Feb 2018 Planned primary completion date changed from 1 May 2017 to 8 Sep 2018.